Abstract
Biopharmaceutical contact centers are expanding core skill sets when it comes to addressing inquiries regarding combination products. An inside look at how biopharmaceutical companies are handling this increasingly common scenario is provided through a benchmark survey, which was conducted between December 2012 and January 2013. The purpose of this survey was to collect and share contact center best practices on the handling of combination products in the biopharmaceutical industry. Eleven biopharmaceutical companies participated in the survey, 10 of which were listed in “The Top 50 Pharmaceutical Companies,” by Pharmaceutical Executive. The information gathered from the survey responses is reported anonymously and provides perspectives on the trends and best practices that will serve as a practical resource for those involved in establishing or expanding contact center services.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
FDA. Combination product definition. http://www.fda.gov/combinationproducts/aboutcombinationproducts/ucm118332.htm. Accessed January 23, 2014.
Nojiri C, Patel C. Call handling in the biopharmaceutical industry: a benchmarking survey. Drug Inf J. 2010;45:337–343.
Guillot P, Fung S. Biopharmaceutical medical information contact centers: results of three benchmarking surveys. Drug Inf J. 2010;44:569–579.
Bowers D, Fish T. Medical information contact centers: challenges and best practices. Drug Inf J. 2013;47:209–213.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jones, S.T., Guillot, P., Poe, T.E. et al. Biopharmaceutical Contact Centers and Combination Products: Results of a Benchmark Survey. Ther Innov Regul Sci 48, 488–493 (2014). https://doi.org/10.1177/2168479014521420
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1177/2168479014521420